Sure, portfolio diversification may be important, but some equity sectors currently look a bit more promising than others.

Key Takeaways:

• Diversification may be a valuable portfolio approach, but individual equity sectors like healthcare may warrant concentrated exposure.
• Healthcare is benefitting from a menagerie of favorable tailwinds, including strong M&A activity and compelling estimations for health spending in the near-term and long-term.
• The State Street Health Care Select Sector SPDR ETF (XLV) is seeing significant inflows as investors look to gain exposure to this attractive sector.

One such sector is healthcare. To be fair, those who have been keeping an eye on how this sector has been doing across the last year or so are likely not surprised to hear this.

Towards the end of last year, M&A activity in the healthcare sector saw significant acceleration. Back at the end of December 2025, a J.P. Morgan report noted that the biotechnology sector in particular led the way in M&A deals year-to-date, as of October 27, 2025 at the time. Meanwhile, the health care equipment and pharmaceuticals sectors also put up impressive numbers.

Last year’s data is far from the only factor working in favor of the healthcare sector. A report from the Peterson Center on Healthcare projected health spending in the U.S. to reach $5.9 trillion by 2026. Going a step further, the report estimated that health spending will account for more than one fifth of the U.S. economy by 2033.

M&A activity and rising health spending are just two major drops in the bucket to support the rising tide of healthcare momentum. As the sector continues to adapt and evolve through AI adoption, healthcare growth could balloon even beyond present expectations.

XLV Offers Distinct Access to Health Care Giants

For those looking to capitalize on the opportunities in health care, a concentrated approach could prove to pay off. One way to do so is through a fund like the State Street Health Care Select Sector SPDR ETF (XLV).

XLV offers straightforward access to the healthcare sector within the S&P 500 index. This includes companies engaged in biotechnology, pharmaceuticals, healthcare equipment, and far more.

It’s clear that this approach to focused healthcare companies is resonating with the investment community. ETFdb flows data shows that as of April 17, 2026, the fund has seen about $911 million in net inflows year to date.

For more news, information, and analysis, visit our Sector Investing Content Hub.